BioCryst Pharmaceuticals Inc
NASDAQ:BCRX

Watchlist Manager
BioCryst Pharmaceuticals Inc Logo
BioCryst Pharmaceuticals Inc
NASDAQ:BCRX
Watchlist
Price: 10.88 USD 3.03% Market Closed
Market Cap: 2.3B USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

BCRX Price Targets Summary
BioCryst Pharmaceuticals Inc

Wall Street analysts forecast BCRX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BCRX is 17.51 USD with a low forecast of 8.08 USD and a high forecast of 31.5 USD.

BCRX Lowest Forecast
Wall Street Target
8.08 USD
26% Downside
BCRX Average Forecast
Wall Street Target
17.51 USD
61% Upside
BCRX Highest Forecast
Wall Street Target
31.5 USD
190% Upside
Lowest
Price Target
8.08 USD
26% Downside
Average
Price Target
17.51 USD
61% Upside
Highest
Price Target
31.5 USD
190% Upside
BioCryst Pharmaceuticals Inc Competitors:
Price Targets
MDXG
MiMedx Group Inc
87% Upside
TECX
AVROBIO Inc
238% Upside
J
7774
Japan Tissue Engineering Co Ltd
109% Upside
MSB
Mesoblast Ltd
78% Upside
MDXG
MiMedx Group Inc
87% Upside
TECX
AVROBIO Inc
238% Upside
J
7774
Japan Tissue Engineering Co Ltd
109% Upside
MSB
Mesoblast Ltd
78% Upside
300294
China Resources Boya Bio pharmaceutical Group Co Ltd
31% Upside
MRNA
Moderna Inc
73% Upside
4587
PeptiDream Inc
116% Upside
600161
Beijing Tiantan Biological Products Corp Ltd
64% Upside

Revenue
Forecast

Revenue Estimate
BioCryst Pharmaceuticals Inc

For the last 8 years the compound annual growth rate for BioCryst Pharmaceuticals Inc's revenue is 43%. The projected CAGR for the next 3 years is 20%.

43%
Past Growth
20%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
BioCryst Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
3%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
BioCryst Pharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-29%
Average Miss
What are analyst estimates?

See Also

Summary
BCRX intrinsic value, competitors valuation, and company profile.
DCF Valuation
BCRX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
BCRX stock valuation using valuation multiples.
Wall Street Estimates
BCRX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
BCRX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is BCRX's stock price target?
Price Target
17.51 USD

According to Wall Street analysts, the average 1-year price target for BCRX is 17.51 USD with a low forecast of 8.08 USD and a high forecast of 31.5 USD.

What is BioCryst Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
20%

For the last 8 years the compound annual growth rate for BioCryst Pharmaceuticals Inc's revenue is 43%. The projected CAGR for the next 3 years is 20%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 258,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.